GlassScriptPhysician profile
Caitlin Stork
NPI 1275254542
$8,679.29
in general payments reported to CMS, 2019-2025
37 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $575 · 2023: $3,327 · 2024: $2,754 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,855 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,855.23 |
| Education | $248.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,390.28 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,220.90 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,025.87 | 2023-2025 | |
| Amgen INC. | $786.19 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $729.90 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $680.28 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $474.63 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $374.43 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.62 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $184.11 | 2023-2025 | Belsomra, Steglatro, Dificid |
| Phathom Pharmaceuticals, INC. | $154.74 | 2024-2025 | Voquezna |
| Pfizer INC. | $123.53 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $104.06 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $93.38 | 2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $91.69 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $90.33 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $82.89 | 2023 | Xarelto, Spravato |
| Antares Pharma, INC. | $81.21 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Azurity Pharmaceuticals, INC. | $72.80 | 2024 | Horizant, Edarbi |
| Sumitomo Pharma America, INC. | $71.13 | 2023-2025 | Gemtesa |
| Ardelyx, INC. | $65.30 | 2024 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $59.15 | 2023-2025 | Rexulti |
| Shield Therapeutics INC | $58.52 | 2024-2025 | |
| Halozyme INC | $57.45 | 2023 | |
| Exact Sciences Corporation | $55.14 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $54.22 | 2024-2025 | Korlym |
| Esperion Therapeutics, INC. | $49.33 | 2023-2024 | Nexletol |
| Mylan Specialty L.P. | $35.63 | 2023-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $32.68 | 2023-2025 | |
| Lundbeck LLC | $30.33 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $29.40 | 2025 | Inspire |
| Vanda Pharmaceuticals INC. | $26.25 | 2023 | Fanapt, Hetlioz |
| Atland Pharmaceuticals, LLC | $22.18 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Kowa Pharmaceuticals America, INC. | $19.00 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $17.05 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.92 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $14.77 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Stork listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.